Home / Market News / $VCYT
benzinga Corporate Catalyst Impact 65/100 ● neutral

Veracyte To Present New Findings From Retrospective Ancillary Analysis Of Randomized Phase III NRG/RTOG 0815 Trial At 2026 ASTRO Annual Meeting

Sep 29, 2026, 12:02 PM UTC · Primary ticker $VCYT

Veracyte announced new findings from a retrospective analysis of a Phase III trial, demonstrating that its Decipher Prostate Genomic Classifier can predict which intermediate-risk prostate cancer patients benefit from adding short-term ADT to radiation. This provides Level 1B1 prognostic and predictive evidence, extending the diagnostic's utility in treatment selection.

Veracyte announced that its Decipher Prostate Genomic Classifier has shown new predictive capabilities in a retrospective analysis of a Phase III trial. The study found that patients with higher Decipher scores benefited significantly from adding short-term androgen deprivation therapy (ADT) to radiation, while those with low scores did not. This is important because it provides Level 1B1 evidence, strengthening Decipher's role in guiding treatment decisions for intermediate-risk prostate cancer, moving beyond just risk assessment. For traders, this represents a positive long-term catalyst for VCYT, as it enhances the clinical utility and market positioning of a core product, potentially leading to increased adoption and revenue. The short-term impact might be moderate as the presentation is in 2026, but it solidifies the company's diagnostic leadership.

$VCYT positive Expanded utility and validation of key product
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.